exagamglogene autotemcel
E1188107
UNEXPLORED
Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
All labels observed (1)
| Label | Occurrences |
|---|---|
| exagamglogene autotemcel canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T15982906 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: exagamglogene autotemcel Context triple: [Vertex Pharmaceuticals, hasClinicalProgram, exagamglogene autotemcel]
-
A.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
B.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
C.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
-
D.
daratumumab
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
E.
isatuximab
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: exagamglogene autotemcel Target entity description: Exagamglogene autotemcel is an investigational CRISPR/Cas9-based gene-editing therapy being developed to treat inherited blood disorders such as sickle cell disease and transfusion-dependent beta thalassemia.
-
A.
Kymriah
Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
-
B.
onasemnogene abeparvovec
Onasemnogene abeparvovec is a gene therapy medication that delivers a functional copy of the SMN1 gene to treat infants and young children with certain forms of spinal muscular atrophy.
-
C.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
-
D.
daratumumab
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
-
E.
isatuximab
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.